{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:03:55Z","timestamp":1768529035487,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bbmt.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T14:37:43Z","timestamp":1531838263000},"page":"2310-2315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-4505","authenticated-orcid":false,"given":"Chien-Ting","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-An","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jih-Luh","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.bbmt.2018.07.013_bib0001","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/bmt.2008.120","article-title":"CMV infections after hematopoietic stem cell transplantation","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0002","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0003","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2009.329","article-title":"The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients","volume":"45","author":"Buyck","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0004","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MOH.0000000000000090","article-title":"Diagnosis and treatment of cytomegalovirus 2013","volume":"21","author":"Einsele","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0005","first-page":"603","article-title":"Seroprevalence of CMV antibodies in a blood donor population and premature neonates in the south-central Taiwan","volume":"15","author":"Lu","year":"1999","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0006","series-title":"Paper presented at the annual meeting of the Asia Pacific Blood and Marrow Transplantation, Oct 30 to Nov 1, 2015. Okinawa, Japan.","article-title":"Cytomegalovirus infection after hematopoietic stem cell transplantation\u2014updated data from Taiwan Blood and Marrow Transplantation Registry (TBMTR)","author":"Bor-Sheng Ko","year":"2015"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0007","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.bbmt.2014.08.010","article-title":"Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review","volume":"20","author":"Sousa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/asheducation-2011.1.305","article-title":"Complications, diagnosis, management, and prevention of CMV infections: current and future","volume":"2011","author":"Boeckh","year":"2011","journal-title":"Hematology."},{"key":"10.1016\/j.bbmt.2018.07.013_bib0009","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/14712598.2012.693471","article-title":"Therapeutic strategies for the prevention and treatment of cytomegalovirus infection","volume":"12","author":"Sellar","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0010","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12879-017-2854-2","article-title":"Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients","volume":"17","author":"Robin","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0011","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature07209","article-title":"Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection","volume":"455","author":"Soroceanu","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0012","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nmicrobiol.2016.82","article-title":"Platelet-derived growth factor-alpha receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer","volume":"1","author":"Kabanova","year":"2016","journal-title":"Nat Microbiol"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2018.07.013_bib0013","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0014","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0016","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0017","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-10-2922","article-title":"Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy","volume":"17","author":"Kantarjian","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0018","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0019","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0020","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/JCM.00797-08","article-title":"Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients","volume":"46","author":"Gimeno","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1705213","article-title":"Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies\/ml: a safe and effective strategy for allogeneic stem cell transplant patients","volume":"37","author":"Verkruyse","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0022","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0023","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0024","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.antiviral.2013.03.017","article-title":"Entry inhibitors and their use in the treatment of HIV-1 infection","volume":"98","author":"Haqqani","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0026","doi-asserted-by":"crossref","first-page":"16511","DOI":"10.1074\/jbc.H117.791731","article-title":"How entry inhibitors synergize to fight HIV","volume":"292","author":"Melikyan","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0027","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0028","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s40265-017-0769-2","article-title":"Drugs in development for hepatitis B","volume":"77","author":"Dawood","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006281","article-title":"Human cytomegalovirus glycoprotein complex gH\/gL\/gO uses PDGFR-alpha as a key for entry","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006273","article-title":"A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells","volume":"13","author":"Stegmann","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0031","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"Tanaka","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0032","doi-asserted-by":"crossref","unstructured":"Kennedy L, Cavalier M, Howard D. Relationship of CMV reactivation and rabbit antithymocyte globulin administration in allogeneic stem cell transplant patients. Biol Blood Marrow Transplant. 2017;23:S282.","DOI":"10.1016\/j.bbmt.2016.12.191"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0033","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbmt.2012.07.004","article-title":"Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia","volume":"18","author":"Atta","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0034","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbmt.2018.07.013_bib0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kroger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0036","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.exphem.2006.10.001","article-title":"Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function","volume":"35","author":"Sharma","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2016.01.022","article-title":"Beneficial effects of nilotinib, tyrosine kinase inhibitor on cyclosporine-A induced renal damage in rats","volume":"33","author":"Nader","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0038","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"issue":"suppl 4","key":"10.1016\/j.bbmt.2018.07.013_bib0039","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1093\/cid\/cit585","article-title":"Prevention of maternal-fetal transmission of cytomegalovirus","volume":"57","author":"Adler","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0956462414536146","article-title":"Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia","volume":"26","author":"Mattioni","year":"2015","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0041","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/375843","article-title":"Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360)","volume":"37","author":"Erice","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0042","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4254\/wjh.v6.i6.370","article-title":"Management of cytomegalovirus infection and disease in liver transplant recipients","volume":"6","author":"Bruminhent","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0043","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1016\/j.transproceed.2014.09.012","article-title":"Cytomegaloviral infection in solid organ transplant recipients: preliminary report of one transplant center experience","volume":"46","author":"Hryniewiecka","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0044","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/JCM.01670-06","article-title":"Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer","volume":"45","author":"Han","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0045","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2016.05.003","article-title":"Cytomegalovirus infection after CD34(+)-selected hematopoietic cell transplantation","volume":"22","author":"Huang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0046","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/cid\/cir002","article-title":"Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients","volume":"52","author":"Pietersma","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0047","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bmt.1703927","article-title":"Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality","volume":"31","author":"Matthes-Martin","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.013_bib0048","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118304002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118304002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:40Z","timestamp":1761059080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118304002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1083879118304002"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.013","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}